High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab
Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitte...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2015, Jahrgang: 43, Heft: 3, Pages: 489-498 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-015-3175-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00259-015-3175-6
|
| Verfasserangaben: | Tobias Weber, Benedikt Bötticher, Walter Mier, Max Sauter, Susanne Krämer, Karin Leotta, Armin Keller, Anne Schlegelmilch, Ludger Grosse-Hovest, Dirk Jäger, Uwe Haberkorn, Michaela A.E. Arndt, Jürgen Krauss |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1698466145 | ||
| 003 | DE-627 | ||
| 005 | 20230427091655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518r20162015xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-015-3175-6 |2 doi | |
| 035 | |a (DE-627)1698466145 | ||
| 035 | |a (DE-599)KXP1698466145 | ||
| 035 | |a (OCoLC)1341325421 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weber, Tobias |e VerfasserIn |0 (DE-588)1084610361 |0 (DE-627)848568125 |0 (DE-576)456364978 |4 aut | |
| 245 | 1 | 0 | |a High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab |c Tobias Weber, Benedikt Bötticher, Walter Mier, Max Sauter, Susanne Krämer, Karin Leotta, Armin Keller, Anne Schlegelmilch, Ludger Grosse-Hovest, Dirk Jäger, Uwe Haberkorn, Michaela A.E. Arndt, Jürgen Krauss |
| 246 | 3 | 3 | |a High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177 Lu-based CD22-specific radioimmunoconjugate and rituximab |
| 264 | 1 | |c 2016 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 04 September 2015 | ||
| 500 | |a Im Titel ist die Zahl "177" hochgestellt | ||
| 500 | |a Gesehen am 18.05.2020 | ||
| 520 | |a Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin’s lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter 177Lu. Both RICs were evaluated as single agents in a human Burkitt’s lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored. | ||
| 534 | |c 2015 | ||
| 700 | 1 | |a Mier, Walter |d 1966- |e VerfasserIn |0 (DE-588)12029026X |0 (DE-627)69653567X |0 (DE-576)292141599 |4 aut | |
| 700 | 1 | |a Sauter, Max |e VerfasserIn |0 (DE-588)1103516507 |0 (DE-627)86126813X |0 (DE-576)470642033 |4 aut | |
| 700 | 1 | |a Krämer, Susanne |e VerfasserIn |0 (DE-588)1142119386 |0 (DE-627)1001170989 |0 (DE-576)494643684 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Krauß, Jürgen |d 1960- |e VerfasserIn |0 (DE-588)120665301 |0 (DE-627)70490778X |0 (DE-576)292329083 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d Heidelberg [u.a.] : Springer-Verl., 2002 |g 43(2016), 3, Seite 489-498 |h Online-Ressource |w (DE-627)359787258 |w (DE-600)2098375-X |w (DE-576)110279549 |x 1619-7089 |7 nnas |a High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab |
| 773 | 1 | 8 | |g volume:43 |g year:2016 |g number:3 |g pages:489-498 |g extent:10 |a High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00259-015-3175-6 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200518 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 120665301 |a Krauß, Jürgen |m 120665301:Krauß, Jürgen |d 910000 |d 910100 |e 910000PK120665301 |e 910100PK120665301 |k 0/910000/ |k 1/910000/910100/ |p 13 |y j | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 11 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 10 | ||
| 998 | |g 1142119386 |a Krämer, Susanne |m 1142119386:Krämer, Susanne |d 910000 |d 911400 |e 910000PK1142119386 |e 911400PK1142119386 |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 998 | |g 1103516507 |a Sauter, Max |m 1103516507:Sauter, Max |p 4 | ||
| 998 | |g 12029026X |a Mier, Walter |m 12029026X:Mier, Walter |d 910000 |d 911400 |e 910000PM12029026X |e 911400PM12029026X |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 1084610361 |a Weber, Tobias |m 1084610361:Weber, Tobias |d 910000 |e 910000PW1084610361 |k 0/910000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1698466145 |e 3668222185 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"titleAlt":[{"title":"High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177 Lu-based CD22-specific radioimmunoconjugate and rituximab"}],"person":[{"display":"Weber, Tobias","family":"Weber","given":"Tobias","role":"aut"},{"given":"Walter","role":"aut","family":"Mier","display":"Mier, Walter"},{"role":"aut","given":"Max","display":"Sauter, Max","family":"Sauter"},{"display":"Krämer, Susanne","family":"Krämer","role":"aut","given":"Susanne"},{"display":"Jäger, Dirk","family":"Jäger","given":"Dirk","role":"aut"},{"family":"Haberkorn","display":"Haberkorn, Uwe","role":"aut","given":"Uwe"},{"given":"Jürgen","role":"aut","family":"Krauß","display":"Krauß, Jürgen"}],"recId":"1698466145","relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximabEuropean journal of nuclear medicine and molecular imaging","title":[{"subtitle":"official journal of the European Association of Nuclear Medicine (EANM)","title_sort":"European journal of nuclear medicine and molecular imaging","title":"European journal of nuclear medicine and molecular imaging"}],"pubHistory":["29.2002 -"],"note":["Gesehen am 13.02.2023","Ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Heidelberg [u.a.]","publisher":"Springer-Verl.","dateIssuedKey":"2002","dateIssuedDisp":"2002-"}],"id":{"eki":["359787258"],"issn":["1619-7089"],"zdb":["2098375-X"]},"recId":"359787258","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"10","volume":"43","pages":"489-498","year":"2016","text":"43(2016), 3, Seite 489-498","issue":"3"},"language":["eng"]}],"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Tobias Weber, Benedikt Bötticher, Walter Mier, Max Sauter, Susanne Krämer, Karin Leotta, Armin Keller, Anne Schlegelmilch, Ludger Grosse-Hovest, Dirk Jäger, Uwe Haberkorn, Michaela A.E. Arndt, Jürgen Krauss"]},"id":{"doi":["10.1007/s00259-015-3175-6"],"eki":["1698466145"]},"title":[{"title_sort":"High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab","title":"High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab"}],"note":["Published online: 04 September 2015","Im Titel ist die Zahl \"177\" hochgestellt","Gesehen am 18.05.2020"],"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a WEBERTOBIAHIGHTREATM2016 | ||